Literature DB >> 25307733

Vasectomy reversal outcomes in men previously on testosterone supplementation therapy.

Robert M Coward1, Douglas A Mata2, Ryan P Smith3, Jason R Kovac4, Larry I Lipshultz4.   

Abstract

OBJECTIVE: To report considerations for preoperative management and outcomes of vasectomy reversal (VR) in men with a history of testosterone supplementation therapy (TST).
METHODS: A retrospective review of men on TST before VR from 2010 to 2013 was performed. For inclusion, patients were required to have baseline and follow-up hormone levels as well as postoperative semen analyses. Preoperative use of medical testicular salvage therapy and testicular sperm aspiration (TESA), intraoperative findings, and pregnancies were also analyzed.
RESULTS: Six of 265 men who underwent VR had prior TST and met inclusion criteria. Median age was 39 years with a median obstructive interval of 7.5 years. Median duration of TST was 9 months before discontinuation and transition to testicular salvage therapy with clomiphene citrate with or without human chorionic gonadotropin for a median of 2.8 months. At baseline, decreased luteinizing hormone (median, 2 mIU/mL), follicle stimulating hormone (median, 5 mIU/mL), and total testosterone (median, 249 ng/dL) were observed. Two men (33%) with uncertain recovery of spermatogenesis based on physical examination and hormone response underwent preoperative testicular sperm aspiration confirming the presence of sperm. Nine vasovasostomies and 3 epididymovasostomies were performed. Patency was 83% after a median follow-up of 6.4 months and was 100% in men undergoing at least 1 vasovasostomy. Spontaneous pregnancy was achieved by 50% during the follow-up period.
CONCLUSION: Testicular salvage medical therapy may play a role in the preoperative management of VR in men with prior TST. VR after TST can have outcomes comparable to those in the general population.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25307733     DOI: 10.1016/j.urology.2014.06.081

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy.

Authors:  Taylor P Kohn; Matthew R Louis; Stephen M Pickett; Mark C Lindgren; Jaden R Kohn; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Fertil Steril       Date:  2016-11-14       Impact factor: 7.329

Review 2.  Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).

Authors:  Ankit Desai; Musaab Yassin; Axel Cayetano; Tharu Tharakan; Channa N Jayasena; Suks Minhas
Journal:  Ther Adv Urol       Date:  2022-06-26

Review 3.  Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.

Authors:  J Abram McBride; Robert M Coward
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

4.  ICSI using fresh and frozen PESA-TESA spermatozoa to examine assisted reproductive outcome retrospectively.

Authors:  Aamir Javed; Manjula Kannasandra Ramaiah; Muralidhar Srinivasaih Talkad
Journal:  Obstet Gynecol Sci       Date:  2019-10-28

Review 5.  Vasectomy reversal: a clinical update.

Authors:  Abhishek P Patel; Ryan P Smith
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

Review 6.  A step-by-step guide to office-based sperm retrieval for obstructive azoospermia.

Authors:  Robert M Coward; Jesse N Mills
Journal:  Transl Androl Urol       Date:  2017-08

Review 7.  Vasectomy reversal: decision making and technical innovations.

Authors:  E Will Kirby; Mark Hockenberry; Larry I Lipshultz
Journal:  Transl Androl Urol       Date:  2017-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.